sotorasib will lessen the level or outcome of triazolam by impacting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. If use is unavoidable, confer with the prescribing facts with the CYP3A4 substrate for dosage modificationsatazanavir will enhance the degree or influence of triazolam by influencing hepatic/intestinal enzym

apalutamide will lessen the extent or result of triazolam by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Stay clear of or Use Alternate Drug. Coadministration of apalutamide, a robust CYP3A4 inducer, with medicines which might be CYP3A4 substrates may end up in reduce publicity to these remedies.If unavoidable, observe patients for loss